JP2015508780A - 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物 - Google Patents

免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物 Download PDF

Info

Publication number
JP2015508780A
JP2015508780A JP2014557870A JP2014557870A JP2015508780A JP 2015508780 A JP2015508780 A JP 2015508780A JP 2014557870 A JP2014557870 A JP 2014557870A JP 2014557870 A JP2014557870 A JP 2014557870A JP 2015508780 A JP2015508780 A JP 2015508780A
Authority
JP
Japan
Prior art keywords
patient
das181
virus
infection
sialidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014557870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508780A5 (enExample
Inventor
モス，ロン
リ，ティエジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of JP2015508780A publication Critical patent/JP2015508780A/ja
Publication of JP2015508780A5 publication Critical patent/JP2015508780A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014557870A 2012-02-17 2013-02-19 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物 Pending JP2015508780A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US61/600,545 2012-02-17
US201261727627P 2012-11-16 2012-11-16
US61/727,627 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Publications (2)

Publication Number Publication Date
JP2015508780A true JP2015508780A (ja) 2015-03-23
JP2015508780A5 JP2015508780A5 (enExample) 2016-04-21

Family

ID=48984833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557870A Pending JP2015508780A (ja) 2012-02-17 2013-02-19 免疫不全患者のインフルエンザ及びパラインフルエンザウイルスを処置するための方法、化合物、及び組成物

Country Status (9)

Country Link
US (5) US20130280332A1 (enExample)
EP (1) EP2841092B1 (enExample)
JP (1) JP2015508780A (enExample)
CN (2) CN104203267A (enExample)
AU (3) AU2013221230A1 (enExample)
CA (1) CA2864746A1 (enExample)
ES (1) ES2970401T3 (enExample)
IL (2) IL234116B (enExample)
WO (1) WO2013123521A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
MX373121B (es) 2010-05-14 2020-04-30 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
CA2799381A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
KR20160072261A (ko) 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
EP3177626A4 (en) 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
KR20170081213A (ko) 2014-11-06 2017-07-11 다나-파버 캔서 인스티튜트 인크. Ezh2 억제제 및 그의 용도
CA2966336A1 (en) * 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
US20180177852A1 (en) * 2015-06-08 2018-06-28 Ansun Biopharma, Inc. Treatment of human metapneumovirus
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
EP3445365A4 (en) 2016-04-22 2019-10-16 Dana-Farber Cancer Institute, Inc. EZH2 INHIBITORS AND USES THEREOF
EP4065139A1 (en) * 2019-11-25 2022-10-05 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524667A (ja) * 2006-01-24 2009-07-02 ネクスバイオ，インク． 高分子マイクロスフェアの調製技術
WO2011057081A1 (en) * 2009-11-06 2011-05-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
JP4933046B2 (ja) * 2002-09-06 2012-05-16 フィリップ モーリス ユーエスエー インコーポレイテッド 液体エアロゾル製剤、エアロゾル発生装置およびエアロゾル発生方法
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524667A (ja) * 2006-01-24 2009-07-02 ネクスバイオ，インク． 高分子マイクロスフェアの調製技術
WO2011057081A1 (en) * 2009-11-06 2011-05-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL INFECTIOUS DISEASES, vol. 53, no. 7, JPN6016046059, 2011, pages 77 - 80, ISSN: 0003451325 *
JOURNAL OF INFECTIOUS DISEASES, vol. 202, no. 2, JPN6016046060, 2010, pages 234 - 241, ISSN: 0003451326 *

Also Published As

Publication number Publication date
ES2970401T3 (es) 2024-05-28
EP2841092C0 (en) 2023-12-06
US20210046165A1 (en) 2021-02-18
AU2019226190A1 (en) 2019-09-26
IL273194B2 (en) 2023-02-01
IL234116B (en) 2020-03-31
CN104203267A (zh) 2014-12-10
IL273194B (en) 2022-10-01
EP2841092A1 (en) 2015-03-04
EP2841092A4 (en) 2015-09-16
WO2013123521A1 (en) 2013-08-22
US20130280332A1 (en) 2013-10-24
US20170151315A1 (en) 2017-06-01
CN109529026A (zh) 2019-03-29
CA2864746A1 (en) 2013-08-22
US20250387457A1 (en) 2025-12-25
AU2019226190B2 (en) 2021-10-07
IL273194A (en) 2020-04-30
AU2017258955A1 (en) 2017-12-14
AU2013221230A1 (en) 2014-10-02
EP2841092B1 (en) 2023-12-06
HK1207975A1 (en) 2016-02-19
US20150132274A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
Rajnik et al. Features, evaluation, and treatment of coronavirus (COVID-19)
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2023134593A (ja) ライノウイルス感染症の予防又は治療のための薬物
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
CN112546046B (zh) 盐酸阿比朵尔在制备治疗肺纤维化疾病药物中的应用
JP2023526200A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の予防または治療のための適合溶質
US12083135B2 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
WO2020109621A1 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
CN108926707A (zh) Pf4的抗rsv应用
EP4248986A1 (en) Use of polypeptide having superoxide dismutase activity and extracellular vesicles for treatment or prevention of respiratory viral infection
KR20230124613A (ko) 바이러스 유래의 호흡기 감염을 치료하기 위한 펩타이드
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
US20250222075A1 (en) Novel application of human airway surfactant, bpifa1, as prophylactic antiviral against respiratory syncytial virus (rsv)
EP4507720A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
Qiu et al. Analysis on Diagnosis of Family Clustering Infection of SARS-CoV-2
WO2024005563A1 (ko) 편도유래줄기세포를 유효성분으로 포함하는 감염성 폐 질환의 예방 또는 치료용 조성물
WO2021195883A1 (zh) TFF2蛋白和IFN-κ蛋白联用在治疗新型冠状病毒感染中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171107